Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.54 |
| ▸ | PIM1 | P11309 | 1/20 | 0.54 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TYMS | P04818 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | TNKS | O95271 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL874078 | 0.85 | PARP1 (0.54) | PARP1CHEK1PIM1RPS6KA3ALDH1A1 | |
| SCHEMBL10985206 | 0.78 | DAO (0.43) | PARP1ALDH1A1LMNAMAPTKDM4E | |
| SCHEMBL873653 | 0.78 | ALDH1A1 (0.54) | PARP1CHEK1ALDH1A1LMNAMAPT | |
| SCHEMBL30089426 | 0.78 | DAO (0.43) | PARP1ALDH1A1LMNAMAPTKDM4E | |
| SCHEMBL38658683 | 0.78 | METAP2 (0.43) | CHEK1PIM1RPS6KA3MAPTTYMS | |
| SCHEMBL10987574 | 0.78 | METAP2 (0.43) | CHEK1PIM1RPS6KA3MAPTTYMS | |
| SCHEMBL874942 | 0.77 | TUBB4A (0.46) | PARP1ALDH1A1LMNAMAPTKDM4E | |
| SCHEMBL13820080 | 0.76 | PARP1 (0.45) | PARP1CHEK1PIM1RPS6KA3LMNA | |
| SCHEMBL17950683 | 0.74 | TYMS (0.40) | PIM1ALDH1A1TYMS | |
| SCHEMBL1843189 | 0.74 | PARP1 (0.58) | PARP1ALDH1A1MAPTKDM4ETNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016116058-A1 | TRIAZINE HETEROCYCLIC COMPOUND WITH NEMATICIDAL ACTIVITY AND PREPARATION METHOD THEREFOR AND USAGE THEREOF | 华东理工大学 | 2016-07-28 | — | — | WO | disclosed |
| US-9187469-B2 | Morpholinylbenzotriazines for use in cancer therapy | MERCK PATENT GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| WO-2015150366-A1 | CYCLICALLY SUBSTITUTED PHENOL ETHER DERIVATIVES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015150364-A1 | SUBSTITUTED BENZOTRIAZINONE BUTANE ACIDS AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-10-08 | — | — | WO | disclosed |
| US-8846910-B2 | Matrix metalloproteinase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2014-09-30 | — | — | US | disclosed |
| US-20140275072-A1 | MORPHOLINYLBENZOTRIAZINES FOR USE IN CANCER THERAPY | MERCK PATENT GMBH (DE) | 2014-09-18 | — | — | US | disclosed |
| US-8816073-B2 | Matrix metalloproteinase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2014-08-26 | — | — | US | disclosed |
| US-20130302378-A1 | MATRIX METALLOPROTEINASE INHIBITORS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2013-11-14 | — | — | US | disclosed |
| US-20130295141-A1 | MATRIX METALLOPROTEINASE INHIBITORS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2013-11-07 | — | — | US | disclosed |
| US-8507670-B2 | Matrix metalloproteinase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2013-08-13 | — | — | US | disclosed |
| US-7842805-B2 | Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof | MYREXIS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-20100081610-A1 | MATRIX METALLOPROTEINASE INHIBITORS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2010-04-01 | — | — | US | disclosed |
| EP-1833803-A4 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS INC (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-2074093-A2 | MATRIX METALLOPROTEINASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008023336-A2 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2008-02-28 | — | — | WO | disclosed |
| US-20080020985-A1 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080020985-A1 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080020985-A1 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| EP-1833803-A2 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006074223-A2 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130302378-A1 | MATRIX METALLOPROTEINASE INHIBITORS | MMP9, MMP8, MMP25 | PARP1 1037/4885CHEK1 4715/4885PIM1 3630/4885 |
| US-20130295141-A1 | MATRIX METALLOPROTEINASE INHIBITORS | MMP9, MMP8, MMP25 | PARP1 1037/4885CHEK1 4715/4885PIM1 3630/4885 |
| US-20140275072-A1 | MORPHOLINYLBENZOTRIAZINES FOR USE IN CANCER THERAPY | TTBK1, TTBK2, SRMS | PARP1 2184/4885CHEK1 68/4885PIM1 312/4885 |
| US-20100081610-A1 | MATRIX METALLOPROTEINASE INHIBITORS | MMP9, MMP8, MMP12 | PARP1 1162/4885CHEK1 4694/4885PIM1 3881/4885 |
| US-20080020985-A1 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CASP3, CASP2, CASP5 | PARP1 400/4885CHEK1 1542/4885PIM1 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.